Mga Batayang Estadistika
| LEI | 549300QE1RU34T50MR69 |
| CIK | 1314102 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to EyePoint Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceutica |
|
| August 7, 2025 |
Filing Fee Table (filed herewith). EXHIBIT FILING FEES Calculation of Filing Fee Table Form S-8 (Form Type) EyePoint Pharmaceuticals, Inc. |
|
| August 7, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| August 6, 2025 |
Exhibit 99.1 EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 |
|
| August 6, 2025 |
FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 29, 2025 |
Investor Presentation July 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2 Legal Disclaimers ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccur |
|
| July 29, 2025 |
Exhibit 99.1 EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration – LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – Over 800 patients enrolled across the LUGANO and LUCIA trials of DURAVYU, r |
|
| July 29, 2025 |
Investor Presentation July 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2 Legal Disclaimers ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccur |
|
| July 29, 2025 |
Exhibit 99.1 EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration – LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – Over 800 patients enrolled across the LUGANO and LUCIA trials of DURAVYU, r |
|
| July 29, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 29, 2025 |
FORM 8-K/A Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 20, 2025 |
EyePoint Pharmaceuticals, Inc. Amendment No 2. to 2023 Long-Term Incentive Plan Exhibit 10.1 EYEPOINT PHARMACEUTICALS, INC. AMENDMENT NO. 2 TO THE 2023 Long Term INCENTIVE PLAN WHEREAS, EyePoint Pharmaceuticals, Inc. (the “Company”) maintains the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan, effective as of June 20, 2023 and amended as of June 20, 2024 (as amended, the “Plan”); WHEREAS, pursuant to Section 9 of the Plan, the Compensation Committee (“Compensati |
|
| May 27, 2025 |
Exhibit 99.1 EyePoint Completes Enrollment in the Pivotal Phase 3 LUGANO Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration – Over 400 patients have been enrolled and randomized over a seven-month period, driven by strong physician and patient interest – – LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion ex |
|
| May 27, 2025 |
FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 27, 2025 |
Investor Presentation May 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2 Legal Disclaimers ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccura |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| May 8, 2025 |
Exhibit 10.1 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of the 31st day of March, 2025 (the “Effective Date”), by and between GRE RIVERWORKS, LLC, a Delaware limited liability company (“Landlord”) (as successor-in-interest to Farley White Aetna Mills, LLC, a Massachusetts limited liability company (“Original Landlord”)), and EYEPOINT PHARM |
|
| May 8, 2025 |
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceutic |
|
| May 7, 2025 |
FORM 8-K Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 7, 2025 |
Exhibit 99.1 EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $3 |
|
| May 7, 2025 |
Investor Presentation May 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2 Legal Disclaimers ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccura |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 6, 2025 |
Exhibit 19.1 EYEPOINT PHARMACEUTICALS, INC. INSIDER TRADING POLICY 1. Introduction and Purpose This Insider Trading Policy (this “Policy”) summarizes the law relating to insider trading and sets out the policy of EyePoint Pharmaceuticals, Inc. (together with its subsidiaries, the “Company” or “EyePoint”) on directors, officers, employees and consultants of the Company (collectively, “Associates”) |
|
| March 6, 2025 |
Exhibit 10.11 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of - by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and - (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, the Board of Direct |
|
| March 6, 2025 |
Subsidiaries of EyePoint Pharmaceuticals, Inc. Exhibit 21.1 List of Subsidiaries of EyePoint Pharmaceuticals, Inc. Subsidiary Name Jurisdiction of Incorporation EyePoint Pharmaceuticals US, Inc. Delaware pSiMedica Limited United Kingdom EyePoint Pharmaceuticals Securities Corporation Massachusetts Icon Bioscience, Inc. Delaware |
|
| March 6, 2025 |
EyePoint Pharmaceuticals, Inc. Incentive Compensation Recovery Policy, dated September 17, 2023 Exhibit 97.1 EyePoint Pharmaceuticals, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of EyePoint Pharmaceuticals, Inc. (the “Company”) on September 17, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. |
|
| March 5, 2025 |
Exhibit 99.1 EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments – Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule - - Positive Phase 2 VERONA clinical trial of DURAVYU for DME met primary and secondary endpoints – – $371 million of cash a |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 04, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 4, 2025 |
TD Cowen Healthcare Conference Presentation March 4, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Confidential Exhibit 99.1 The Leader in Sustained Release Drug Delivery for Retinal Disease ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Durasert® features robust safety profile across multiple indications Compelling DAVIO 2 data enablin |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedu |
|
| February 5, 2025 |
Investor Presentation February 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2 Legal Disclaimers ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially ina |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (C |
|
| February 5, 2025 |
Exhibit 99.1 EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYUTM for Diabetic Macular Edema Meeting Primary and Secondary Endpoints - Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA wi |
|
| January 13, 2025 |
Exhibit 99.2 EyePoint Provides Company Update and Anticipated Development Milestones for 2025 – Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2 VERONA clinical trial of DURAVYU in DME expected in 1Q 2025 – – Appointed renowned retina specialist and industr |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 13, 2025 |
J.P. Morgan Healthcare Conference Presentation January 14, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.1 Legal Disclaimers ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2025 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 8, 2025 |
Exhibit 99.1 EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors WATERTOWN, Mass., January 8, 2025 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appo |
|
| December 4, 2024 |
Exhibit 99.1 EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration – Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., December 4, 2024 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative |
|
| December 4, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 04, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (C |
|
| November 14, 2024 |
EYPT / EyePoint Pharmaceuticals, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 cormorant-eypt093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30233G209 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 12, 2024 |
EYPT / EyePoint Pharmaceuticals, Inc. / Adage Capital Management, L.P. Passive Investment SC 13G/A 1 p24-3045sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30233G209 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the approp |
|
| November 7, 2024 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Memorandum of Understanding This Memorandum of Understanding, (the “2024 MOU”), dated as of August 26, 2024 (“Effective Date”), is entered into by and between EyePoint Pharmaceut |
|
| November 7, 2024 |
EX-99.1 2 d791430dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that |
|
| November 7, 2024 |
EYPT / EyePoint Pharmaceuticals, Inc. / TCG Crossover GP II, LLC - SC 13G Passive Investment SC 13G 1 d791430dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 30233G209 (CUSIP Number) October 31, 2024 (Date of Event Which Requires Filing of This Statement) Che |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (C |
|
| November 7, 2024 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments – Announced positive interim data for DURAVYU 2.7mg in DME demonstrating meaningful, early and sustained visual acuity gains, strong anatomical control and a continued favorable safety profile; BCVA and CST improvement of +8.9 letters and -68 microns, respectively, at 16- |
|
| November 7, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (this “Amendment”) is dated as of September 30, 2024 (the “Effective Date”) by and between 600 CPK LLC, a Delaware limited liability company (“Lessor”), and EYEPOINT PHARMACEUTICALS US, INC., a Delaware corporation (“Lessee”). WHEREAS, Lessor, successor in interest to V.E. Properties IX, LLC, and Lessee are parties to that certain |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmace |
|
| November 6, 2024 |
EYPT / EyePoint Pharmaceuticals, Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G 1 eyepointpharmaceuticals13g.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) EYEPOINT PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 30233G209 (CUSIP Number) October 31, 20 |
|
| October 31, 2024 |
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock EXHIBIT 99.1 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock WATERTOWN, Mass., October 28, 2024 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offerin |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-51122 26-2774444 (State or other jurisdiction of incorporation) (Co |
|
| October 31, 2024 |
EXHIBIT 99.3 EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares WATERTOWN, Mass., October 31, 2024 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced |
|
| October 31, 2024 |
EXHIBIT 1.1 EYEPOINT PHARMACEUTICALS, INC. 12,727,273 Shares of Common Stock UNDERWRITING AGREEMENT October 29, 2024 J.P. MORGAN SECURITIES LLC As Representative of the several Underwriters c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: 1. INTRODUCTORY. EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell, pursu |
|
| October 31, 2024 |
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering EXHIBIT 99.2 EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering WATERTOWN, Mass., October 29, 2024 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 12,727,2 |
|
| October 30, 2024 |
Joint Book-Running Managers J.P. Morgan Citigroup Guggenheim Securities Baird Mizuho Jones Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281391 Prospectus Supplement (To prospectus dated August 16, 2024) 12,727,273 Shares EyePoint Pharmaceuticals, Inc. Common Stock We are offering 12,727,273 shares of our common stock, par value $0.001 per share, at a public offering price of $11.00 per share of common stock. Our common stock is listed on The Nasdaq Global Mark |
|
| October 28, 2024 |
Exhibit 99.1 EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYUTM for Diabetic Macular Edema - DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline - – DURAVYU 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron re |
|
| October 28, 2024 |
Investor Presentation October 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.2 Legal Disclaimers ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inac |
|
| October 28, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281391 The information in this preliminary prospectus supplement is not complete and may be changed. The registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell thes |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 24, 2024 |
Exhibit 99.1 EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration – Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 – – Topline data anticipated in 2026 – WATERTOWN, Mass., October 24, 2024 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), |
|
| October 24, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 03, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) ( |
|
| September 4, 2024 |
Exhibit 99.1 EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors - Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYUTM in wet AMD in 2024 - WATERTOWN, Mass., September 4, 2024 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commerciali |
|
| August 14, 2024 |
EYEPOINT PHARMACEUTICALS, INC. 480 Pleasant Street Watertown, MA 02472 EYEPOINT PHARMACEUTICALS, INC. 480 Pleasant Street Watertown, MA 02472 August 14, 2024 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Benjamin Richie Re: EyePoint Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 8, 2024 File No. 333-281391 Request for Acceleration of Effective Date Dear Benjamin |
|
| August 8, 2024 |
As filed with the Securities and Exchange Commission on August 8, 2024 S-8 1 d845604ds8.htm S-8 As filed with the Securities and Exchange Commission on August 8, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or other jurisdiction of inco |
|
| August 8, 2024 |
Exhibit 10.3 SEVERANCE AGREEMENT AND GENERAL RELEASE This Severance Agreement and General Release (this “Agreement”) is entered into by Nancy S. Lurker (“Employee”) and EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”). This Agreement is effective only if it has been executed by the parties on or after the Separation Date and the revocation period has expired without revocation as set f |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceutica |
|
| August 8, 2024 |
As filed with the Securities and Exchange Commission on August 8, 2024 S-3 1 d881350ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EYEPOINT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or other j |
|
| August 8, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) EyePoint Pharmaceuticals, Inc. |
|
| August 8, 2024 |
Form of Indenture (filed herewith). Exhibit 4.5 INDENTURE DATED AS OF , 20 BETWEEN EYEPOINT PHARMACEUTICALS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04 Ac |
|
| August 8, 2024 |
Filing Fee Table (filed herewith). EX-FILING FEES 4 d845604dexfilingfees.htm EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) EyePoint Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee |
|
| August 7, 2024 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments – Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient dosing in 2024 – – Positive twelve-month data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD continue to demonstrate favorable s |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 26, 2024 |
UNIVERSITY CLUB | NEW YORK CITY | JUNE 26, 2024 ©2024 EyePoint Pharmaceuticals, Inc. |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commis |
|
| June 26, 2024 |
Exhibit 99.2 EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 – Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data |
|
| June 21, 2024 |
Exhibit 10.1 EYEPOINT PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO THE 2023 Long Term INCENTIVE PLAN WHEREAS, EyePoint Pharmaceuticals, Inc. (the “Company”) maintains the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan, effective as of June 20, 2023 (the “Plan”); WHEREAS, pursuant to Section 9 of the Plan, the Compensation Committee (“Compensation Committee”) of the Board of Directors of |
|
| June 21, 2024 |
EyePoint Pharmaceuticals, Inc. Amendment No 2. to 2019 Employee Stock Purchase Plan Exhibit 10.2 EYEPOINT PHARMACEUTICALS, INC. AMENDMENT NO. 2 TO THE 2019 EMPLOYEE STOCK PURCHASE PLAN WHEREAS, EyePoint Pharmaceuticals, Inc. (the “Company”) maintains the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan, which was originally effective as of July 1, 2019 and amended as of June 22, 2021 (as amended, the “ESPP”); WHEREAS, pursuant to Section 13(b) of the ESPP, the Com |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 28, 2024 |
Investor Presentation May 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.1 Legal Disclaimers ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccura |
|
| May 9, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (hereinafter the “Agreement”) is made as of March 1, 2024 (the “Effective Date”), by and between Ramiro Ribeiro, M.D., Ph.D, who currently resides at *** (“Employee”) and EyePoint Pharmaceuticals, Inc. (hereinafter together with its subsidiaries, and related or affiliated entities referred to as the “Company”), having its headquarters at |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceutic |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 8, 2024 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments – Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU™ in wet AMD in 2H 2024 – – $299 million of cash and investments on March 31, 2024, with cash runway through topline data of Phase 3 trials for DURAVYU for wet AMD in 2026 – – Compan |
|
| May 6, 2024 |
Exhibit 99.1 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy – DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no drug-related serious adverse events – – Conference call |
|
| May 6, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 06, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 6, 2024 |
DURAVYU™ in NPDR PAVIA Phase 2 Clinical Trial Topline Results May 6, 2024 ©2024 EyePoint Pharmaceuticals, Inc. |
|
| May 1, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30233G209 (CUSIP Number) April 30, 2024** (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| April 30, 2024 |
SC 13G 1 p24-1502sc13g.htm EYEPOINT PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30233G209 (CUSIP Number) April 30, 2024 (Date of Event Which Requires Filing of This Statem |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 8, 2024 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of EyePoint Pharmaceuticals, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. |
|
| March 8, 2024 |
Exhibit 10.21 CONSULTING AGREEMENT between EYEPOINT PHARMACEUTICALS US, INC. and John Landis, PhD THIS Consulting Agreement (the “Agreement”), effective as of December 18, 2023 (the “Effective Date”), is entered into between John Landis, PhD (“Consultant”) and EyePoint Pharmaceuticals US, Inc. (“EyePoint”), a corporation organized under the laws of the State of Delaware. EyePoint desires to retain |
|
| March 8, 2024 |
Form of Stock Option Award for Inducement Grants to executive officer pursuant to the 2023 LTIP Exhibit 10.20 Nonstatutory Stock Option Executive Officer Inducement Award 1. Grant of Option. This certificate evidences a nonstatutory stock option (this “Stock Option”) granted by EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on ###GRANTDATE### (the "Date of Grant") to ###PARTICIPANTNAME### (the "Participant"). This Stock Option is granted to the Participant in connect |
|
| March 8, 2024 |
Exhibit 10.17 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of - by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and - (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, the Board of Direct |
|
| March 8, 2024 |
Subsidiaries of EyePoint Pharmaceuticals, Inc. Exhibit 21.1 List of Subsidiaries of EyePoint Pharmaceuticals, Inc. Subsidiary Name Jurisdiction of Incorporation EyePoint Pharmaceuticals US, Inc. Delaware pSiMedica Limited United Kingdom EyePoint Pharmaceuticals Securities Corporation Massachusetts Icon Bioscience, Inc. Delaware |
|
| March 8, 2024 |
EyePoint Pharmaceuticals, Inc. Incentive Compensation Recovery Policy, dated September 17, 2023 Exhibit 97.1 EyePoint Pharmaceuticals, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of EyePoint Pharmaceuticals, Inc. (the “Company”) on September 17, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in |
|
| March 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 7, 2024 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments – Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 – – Dosed first patient in Phase 2 |
|
| March 4, 2024 |
Exhibit 99.1 EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer – Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR – – Initiation of first Phase 3 clinical trial (LUGANO) of EYP-1901 in wet AMD expected in 2H 2024 – WATERTOWN, Mass, March 4, 2024 (GLOBE NEWSWIR |
|
| March 4, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 04, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 14, 2024 |
EYPT / EyePoint Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30233G209 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 14, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm246065d28ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| February 13, 2024 |
EYPT / EyePoint Pharmaceuticals, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1096305513g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 30233G209 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 7, 2024 |
SC 13G/A 1 p24-0429sc13ga.htm EYEPOINT PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30233G209 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of Th |
|
| February 6, 2024 |
EYPT / EyePoint Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment eyep23a5.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 30233G209 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 30233G209 (CUSIP Number) December 31, 2023 (Date o |
|
| January 10, 2024 |
Exhibit 99.2 EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema WATERTOWN, Mass., January 10, 2024 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today annou |
|
| January 10, 2024 |
J.P. Morgan Healthcare Conference Presentation January 10, 2024 Jay Duker, M.D. President and CEO ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.1 Legal Disclaimers ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30233G209 (CUSIP Number) December 4, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| December 8, 2023 |
EYPT / EyePoint Pharmaceuticals Inc / EW Healthcare Partners, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d884875dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30233G100 (CUSIP Number) Ronald W. Eastman EW Healthcare Partners L.P. 21 Waterway Avenue, Suit |
|
| December 8, 2023 |
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock WATERTOWN, Mass., December 4, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering o |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-51122 26-2774444 (State or other jurisdiction of incorporation) (Co |
|
| December 8, 2023 |
EX-1.1 Exhibit 1.1 EYEPOINT PHARMACEUTICALS, INC. 11,764,706 Shares of Common Stock UNDERWRITING AGREEMENT December 5, 2023 J.P. MORGAN SECURITIES LLC As Representative of the several Underwriters c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: 1. INTRODUCTORY. EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell |
|
| December 8, 2023 |
Joint Filing Agreement, dated December 8, 2023 EX-99.1 2 d884875dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D relating to the Common Stock of EyePoint Pharmaceuticals, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13D will, unless written notice to the contrary is delivered as described below, be jo |
|
| December 8, 2023 |
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock WATERTOWN, Mass., December 4, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering o |
|
| December 8, 2023 |
EX-99.3 Exhibit 99.3 EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares WATERTOWN, Mass., December 8, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-51122 26-2774444 (State or other jurisdiction of incorporation) (Co |
|
| December 8, 2023 |
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering EX-99.2 Exhibit 99.2 EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering WATERTOWN, Mass., December 5, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,764,706 |
|
| December 8, 2023 |
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering EX-99.2 Exhibit 99.2 EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering WATERTOWN, Mass., December 5, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,764,706 |
|
| December 7, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275125 Prospectus Supplement (To prospectus dated October 30, 2023) 11,764,706 Shares EyePoint Pharmaceuticals, Inc. Common Stock We are offering 11,764,706 shares of our common stock, par value $0.001 per share, at a public offering price of $17.00 per share of common stock. Our common stock is listed on The Nasdaq Glob |
|
| December 4, 2023 |
EYP-1901 in wet AMD DAVIO 2 Phase 2 Clinical Trial Topline Data December 4, 2023 ©2023 EyePoint Pharmaceuticals, Inc. |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 04, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (C |
|
| December 4, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints - Both EYP-1901 cohorts demonstrated a statistically non-inferior change in BCVA versus aflibercept control with a numerical difference of only -0.3 and -0.4 letters, respectively for the 2 mg and 3 mg dose at blended six-month en |
|
| December 4, 2023 |
EyePoint Pharmaceuticals, Inc. 480 Pleasant Street Watertown, MA 02472 Telephone: (617) 926-5000 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275125 The information in this preliminary prospectus supplement is not complete and may be changed. The registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell thes |
|
| November 9, 2023 |
Virtual KOL Event November 9, 2023 ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.1 Forward-Looking Statements ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potenti |
|
| November 9, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (C |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmace |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (C |
|
| November 1, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments – Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic SAEs reported – – Leadership strengthened with the appointment of Stuart Duty to the Board of Directors and |
|
| October 26, 2023 |
EYEPOINT PHARMACEUTICALS, INC. 480 Pleasant Street Watertown, MA 02472 EYEPOINT PHARMACEUTICALS, INC. 480 Pleasant Street Watertown, MA 02472 October 26, 2023 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jane Park Re: EyePoint Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed October 20, 2023 File No. 333-275125 Request for Acceleration of Effective Date Dear Jane Park: |
|
| October 20, 2023 |
Filing Fee Table (filed herewith). EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) EyePoint Pharmaceuticals, Inc. |
|
| October 20, 2023 |
Form of Indenture (filed herewith). Exhibit 4.6 INDENTURE DATED AS OF , 20 BETWEEN EYEPOINT PHARMACEUTICALS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04 Ac |
|
| October 20, 2023 |
Filing Fee Table (filed herewith). EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) EyePoint Pharmaceuticals, Inc. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 20, 2023 Table of Contents As filed with the Securities and Exchange Commission on October 20, 2023 Registration No. |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 20, 2023 As filed with the Securities and Exchange Commission on October 20, 2023 Registration No. |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 16, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team - Stuart Duty appointed to EyePoint’s Board of Directors – - George Elston promoted to Executive Vice President - WATERTOWN, Mass., October 16, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients |
|
| September 13, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) ( |
|
| September 13, 2023 |
Investor Presentation September 2023 Exhibit 99.1 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect |
|
| September 11, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 - Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related ocular or systemic serious adverse events in Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopath |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) ( |
|
| September 11, 2023 |
EYPT / EyePoint Pharmaceuticals Inc / FRANKLIN RESOURCES INC Passive Investment eyep23a4.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 30233G209 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 30233G209 (CUSIP Number) August 31, 2023 (Date of |
|
| August 30, 2023 |
EYPT / EyePoint Pharmaceuticals Inc / EW Healthcare Partners, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d543563dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30233G100 (CUSIP Number) Ronald W. Eastman EW Healthcare Partners L.P. 21 Waterway Avenue, Suit |
|
| August 30, 2023 |
EX-99.1 2 d543563dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D relating to the Common Stock of EyePoint Pharmaceuticals, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13D will, unless written notice to the contrary is delivered as described below, be jo |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceutica |
|
| August 2, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments –Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023 – –Phase 2 PAVIA clinical trial evaluating EYP-1901 in non-proliferative diabetic retinopathy remains on track with toplin |
|
| August 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 27, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit - Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is well tolerated with no reported drug-related ocular or systemic SAEs - - Patient demographics demonstrate the Phase 2 DAVIO 2 population has |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 27, 2023 |
Nancy Lurker, Executive Vice Chair, Board of Directors | OIS | July 27, 2023 Spotlight on Drug Delivery Exhibit 99. |
|
| July 11, 2023 |
Investor Presentation July 2023 Exhibit 99.1 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, pla |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 10, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Announces Chief Executive Officer Transition – Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S. Lurker Transitions to Executive Vice Chair of the Board of Directors Pursuant to Long Term Succession Plan WATERTOWN, Mass., July 10, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 10, 2023 |
Exhibit 10.2 SECOND amendment to employment agreement SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), dated as of July 10, 2023, between EyePoint Pharmaceuticals, Inc. (the “Company”), and Jay S. Duker, M.D. (“Employee”). W I T N E S S E T H WHEREAS, the Company and Employee have previously entered into that certain Amended and Restated Employment Agreement, effective as of November 1 |
|
| July 10, 2023 |
Exhibit 10.1 SECOND amendment to employment LETTER agreement SECOND AMENDMENT TO EMPLOYMENT LETTER AGREEMENT (this “Amendment”), dated as of July 10, 2023, between EyePoint Pharmaceuticals, Inc. (the “Company”), and Nancy S. Lurker (“Employee”). W I T N E S S E T H WHEREAS, the Company and Employee have previously entered into that certain employment letter agreement, dated September 15, 2016, as |
|
| June 21, 2023 |
Exhibit 10.1 EYEPOINT PHARMACEUTICALS, INC. 2023 Long Term INCENTIVE PLAN 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and includes certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock, Stock-based and other incentiv |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 5, 2023 |
Investor Presentation June 2023 Exhibit 99.2 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, pla |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 5, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy – Significant investigator and patient interest drove strong recruitment of 77 patients exceeding the 60 patient target – – Topline PAVIA data anticipated in 2Q 2024 – WATERTOWN, Mass., June 5, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDA |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. |
|
| May 23, 2023 |
Unaudited Pro Forma Condensed Consolidated Financial Information EX-99.1 Exhibit 99.1 Unaudited Pro Forma Condensed Consolidated Financial Information On May 17, 2023 (the “Closing Date”), EyePoint Pharmaceuticals, Inc. (the “Company”) entered into a product rights agreement (the “Product Rights Agreement”) with Alimera Sciences, Inc. (“Alimera”) to grant to Alimera an exclusive (even as to the Company) and sublicensable right and license under the Company’s an |
|
| May 18, 2023 |
EX-10.1 3 eypt-ex101.htm EX-10.1 EXECUTION COPY Confidential CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Exhibit 10.1 COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT (this “Agreement”) is made as of May 17, 2023 (the “Effective D |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 18, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties –$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitalized beyond key EYP-1901 Phase 2 DAVIO 2 and PAVIA clinical trial inflectio |
|
| May 18, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceutic |
|
| May 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 03, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 3, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments – Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023 – Enrollment ahead of schedule in the Phase 2 PAVIA clinical trial evaluating EYP-1901 in non |
|
| May 1, 2023 |
EYPT / EyePoint Pharmaceuticals Inc / Cormorant Global Healthcare Master Fund, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 30233G209 (CUSIP Number) April 21, 2023† (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| May 1, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of May 1, 2023, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 27, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD - Significant investigator and patient interest drove strong recruitment, exceeding enrollment goals - Topline DAVIO 2 data anticipated in Q4 2023 WATERTOWN, Mass., March 27, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT |
|
| March 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 10, 2023 |
Subsidiaries of EyePoint Pharmaceuticals, Inc. Exhibit 21.1 List of Subsidiaries of EyePoint Pharmaceuticals, Inc. Subsidiary Name Jurisdiction of Incorporation EyePoint Pharmaceuticals US, Inc. Delaware pSiMedica Limited United Kingdom EyePoint Pharmaceuticals Securities Corporation Massachusetts Icon Bioscience, Inc. Delaware |
|
| March 10, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 10, 2023 |
Exhibit 10.19 EMPLOYMENT AGREEMENT This Employment Agreement (hereinafter the “Agreement”) is made as of January 3, 2023 (the “Effective Date”), by and between Michael Pine, who currently resides at xxx (“Employee”) and EyePoint Pharmaceuticals, Inc. (hereinafter together with its subsidiaries, and related or affiliated entities referred to as the “Company”), having its headquarters at 480 Pleasan |
|
| March 10, 2023 |
Exhibit 10.40 SECOND Amendment to Loan and security agreement This Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 6th day of December, 2022, by and among (a) SILICON VALLEY BANK (“Bank”) and (b) (i) EYEPOINT PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), (ii) EYEPOINT PHARMACEUTICALS US, INC., a Delaware corporation (“EyePoint US”), and (iii) ICO |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. |
|
| March 10, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 10, 2023 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of EyePoint Pharmaceuticals, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), |
|
| March 10, 2023 |
Exhibit 10.20 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 2023 by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, the Board of Dir |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 10, 2023 |
Exhibit 10.14 EMPLOYMENT AGREEMENT This Employment Agreement (hereinafter the “Agreement”) is made as of January 3, 2023 (the “Effective Date”), by and between Dario Paggiarino, M.D., who currently resides at xxx (“Employee”) and EyePoint Pharmaceuticals, Inc. (hereinafter together with its subsidiaries, and related or affiliated entities referred to as the “Company”), having its headquarters at 4 |
|
| March 10, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 02, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 2, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments – Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy (NPDR) on track with enrollment completion anticipated in 4Q 2023 – – Net product |
|
| February 14, 2023 |
EYPT / Eyepoint Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d28sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30233G209 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this St |
|
| February 13, 2023 |
EYPT / Eyepoint Pharmaceuticals Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d992786313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 30233G209 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| January 31, 2023 |
EYPT / Eyepoint Pharmaceuticals Inc / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 eyep22a31.htm CUSIP NO. 30233G209 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3)* EyePoint Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 30233G209 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of |
|
| January 23, 2023 |
Exhibit 99.1 EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ – State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts – – Awarded $1.9 million of state and local grants with rent commencing in second half of 2024 – WATERTOWN, Mass, January 23, 2023 (GLOBE NEW |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 12, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 12, 2023 |
Investor Presentation January 2023 Exhibit 99.1 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, |
|
| January 9, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) EyePoint Pharmaceuticals, Inc. |
|
| January 9, 2023 |
As filed with the Securities and Exchange Commission on January 9, 2023 S-8 As filed with the Securities and Exchange Commission on January 9, 2023 Registration No. |
|
| January 6, 2023 |
EX-99.2 7 eypt-ex992.htm EX-99.2 Exhibit 99.2 EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer Dr. Duker has served as EyePoint’s Chief Operating Officer since November 2021 WATERTOWN, Mass., January 4, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics |
|
| January 6, 2023 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (hereinafter the ?Agreement?) is made as of January 3, 2023 (the ?Effective Date?), by and between George O. Elston, who currently resides at xxx (?Employee?) and EyePoint Pharmaceuticals, Inc. (hereinafter together with its subsidiaries, and related or affiliated entities referred to as the ?Company?), having its headquarters at 480 Plea |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 03, 2023 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| January 6, 2023 |
Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (hereinafter the ?Agreement?) is made as of January 3, 2023 (the ?Effective Date?), by and between Scott Jones, who currently resides at xxx (?Employee?) and EyePoint Pharmaceuticals, Inc. (hereinafter together with its subsidiaries, and related or affiliated entities referred to as the ?Company?), having its headquarters at 480 Pleasant |
|
| January 6, 2023 |
Exhibit 10.1 FIRST amendment to employment agreement FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), dated as of January 3, 2023, between EyePoint Pharmaceuticals, Inc. (the ?Company?), and Jay S. Duker, M.D. (?Employee?). W I T N E S S E T H WHEREAS, the Company and Employee have previously entered into that certain Amended and Restated Employment Agreement, effective as of November 1 |
|
| January 6, 2023 |
EX-10.2 3 eypt-ex102.htm EX-10.2 Exhibit 10.2 FIRST amendment to employment LETTER agreement FIRST AMENDMENT TO EMPLOYMENT LETTER AGREEMENT (this “Amendment”), dated as of January 3, 2023, between EyePoint Pharmaceuticals, Inc. (the “Company”), and Nancy S. Lurker (“Employee”). W I T N E S S E T H WHEREAS, the Company and Employee have previously entered into that certain employment letter agreeme |
|
| January 6, 2023 |
EX-99.1 6 eypt-ex991.htm EX-99.1 Exhibit 99.1 EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines – Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR – – Full-year 2022 net product revenue estimated to exceed $39.5 millio |
|
| November 16, 2022 |
Investor Presentation November 2022 Exhibit 99.1 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, |
|
| November 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (C |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (C |
|
| November 14, 2022 |
EyePoint Pharmaceuticals, Inc. Amended and Restated 2016 Long Term Incentive Plan, as amended Exhibit 10.1 AMENDMENT No. 4 TO THE EYEPOINT Pharmaceuticals, Inc. amended and restated 2016 Long Term Incentive Plan WHEREAS, EyePoint Pharmaceuticals, Inc. (the “Company”) maintains the EyePoint Pharmaceuticals, Inc. Amended and Restated 2016 Long-Term Incentive Plan, which was originally effective as of December 12, 2016 and amended as of February 21, 2019, June 25, 2019, March 25, 2021 and Jun |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmace |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (C |
|
| November 2, 2022 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments – Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 07, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 29, 2022 |
Exhibit 99.1 EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy WATERTOWN, Mass., September 29, 2022 (GLOBE NEWSWIRE) ? EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serio |
|
| September 29, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) ( |
|
| September 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) ( |
|
| September 28, 2022 |
Investor Presentation September 28, 2022 Exhibit 99.1 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, ex |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 5, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ?[***]?, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 5, 2022 |
Exhibit 10.1 CONFIDENTIAL Execution Version AMENDMENT #1 TO EXCLUSIVE LICENSE AGREEMENT This Amendment #1 (this ?Amendment?), dated as of May 2, 2022 (the ?Amendment Effective Date?), is by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation having offices at 480 Pleasant Street, Watertown, MA 02472 (?EyePoint?), and Equinox Sciences, LLC, a Delaware limited liability company having |
|
| August 5, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ?[***]?, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceutica |
|
| August 3, 2022 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments – First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 18, 2022 |
Exhibit 99.1 EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert? Technology Developments and Provide a Financial Update - Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD announced at ASRS 2022 Annual Meeting - Phase 2 clinical trial (DAVIO 2) in wet AMD and in non-proliferative diabetic retinopathy |
|
| July 18, 2022 |
UNIVERSITY CLUB | NEW YORK CITY | JULY 18, 2022 Exhibit 99.2 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we int |
|
| July 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 EyePoint Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 14, 2022 |
EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors Exhibit 99.1 EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) ? EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Karen Zaderej to its Board of Directors. |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2022 EyePoint Pharmaceuticals, Inc. |
|
| May 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2022 EyePoint Pharmaceuticals, Inc. |
|
| May 13, 2022 |
1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation May 2022 Exhibit 99. |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceutic |
|
| May 4, 2022 |
Exhibit 99.1 EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments ? Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD) at Angiogenesis, Exudation, and Degeneration 2022; Phase 2 clinical trial expected to initiate in Q3 2022 ? ? |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 EyePoint Pharmaceuticals, Inc. |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 14, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ?[***]?, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 14, 2022 |
Exhibit 10.45 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ?[***]?, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. December 6, 2021 VIA EMAIL Imprimis Rx, LLC 12264 El Camino Real Suite 350 San Diego, California 92130 Attn: John Saharek Email: [email protected] Re: Commercial Alliance |
